hrp0084p1-114 | Puberty | ESPE2015

Screening of Mutations in Idiopathic Hypogonadotropic Hypogonadism Using a Targeted Next-Generation Sequencing Approach

Kolodkina Anna , Kareva Maria , Kalinchenko Natalia , Raygorodskaya Nadezhda , Malievsky Oleg , Fidelina Olga , Vasilyev Evgeny , Petrov Vasily , Naumova Maria , Tiulpakov Anatoly

Background: To date at least 30 genes are known to be associated with idiopathic hypogonadotropic hypogonadism (IHH). Analysis of all these gene candidates by Sanger sequencing would be expensive, labour-intensive and time-consuming. Recent introduction of next-generation sequencing (NGS) enables simultaneous analysis of multiple gene targets making it an attractive approach in such conditions as IHHObjective and hypotheses: To study the spectrum of mole...

hrp0084p3-722 | Diabetes | ESPE2015

Social Risk Assessment in Children with Diabetes Mellitus to Plan Medical and Social Care

Karpushkina Anna , Peterkova Valentina , Vartapetova Natalia , Dedyukina Elena , Philimonova Alla , Mikhailova Evgenia , Malievsky Oleg , Samoylova Yulia , Bashnina Elena , Khramova Elena , Shvabsky Oleg , Pankratova Maria , Starovoitov Mikhail

Background: According to the World Health Organization, the social determinants of health, the conditions in which people are born, grow, live and work – significantly influences on health. The CAF Foundation, the Endocrinology Scientific Center and the Institute for Family Health under the Alfa-Endo Program studied prevalence of some social determinants in families of children with type 1 diabetes mellitus.Objective and hypotheses: Investigate soci...

hrp0084fc13.3 | Thyroid | ESPE2015

Targeted Next-Generation Sequencing Demonstrates High Frequency of ‘Dyshormonogenesis Genes’ Mutations in Severe Congenital Hypothyroidism

Makretskaya Nina , Bezlepkina Olga , Kolodkina Anna , Kiyaev Alexey , Vasilyev Evgeny , Petrov Vasily , Kalinenkova Svetlana , Duhoreva Olga , Malievsky Oleg , Dedov Ivan , Tiulpakov Anatoly

Background: 80–85% of cases of congenital hypothyroidism (CH) are shown to be due to thyroid dysgenesis, while 15–20% are due to dyshormonogenesis. At least 12 candidate genes are associated with congenital hypothyroidism (CH), however its molecular basis is defined in fewer than 10% of the patients (ESPE consensus, 2014). Recent studies suggest that using a next generation sequencing (NGS) approach may increase the mutation yield in CH.Objecti...

hrp0082fclb1 | Late Breaking Abstracts | ESPE2014

Top Line Results of Once-Weekly, CTP-Modified Human GH (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency

Zadik Zvi , Rosenfeld Ron , Radziuk Klaudziya , Zelinska Nataliya , Malievsky Oleg , Iotova Violeta , Skorodok Julia , Koren Ronit , Amitzi Leanne , Hart Gili , Herskovitz Oren , Fima Eyal

Objective: GH replacement therapy currently requires daily injections, which may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in GH deficient (GHD) adults and children. Pharmacokinetics (PK), pharmacodynamics, (PD) efficacy and safety analysis of weekly treatment with MOD-4023 in GHD naïve children was performed and compared to daily hGH.Design and metho...

hrp0084fc7.5 | Growth-promoting therapies | ESPE2015

12-Month Safety and Efficacy of a Weekly Long-Acting GH (MOD-4023) Compared to Daily Recombinant Human GH Therapy in Pre-Pubertal GH-Deficient Children; Phase 2 Study: Study CP-4-004 Summary

Zadik Zvi , Rosenfeld Ron , Radziuk Klaudziya , Zelinska Nataliya , Malievsky Oleg , Iotova Violeta , Skorodok Julia , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili

Objective and hypotheses: To compare the PK/PD, safety, efficacy, and tolerability of three doses of once-weekly MOD-4023 to that of a daily recombinant human GH (rhGH) formulation in pre-pubertal children with growth failure due to GH deficiency (GHD).Method: The randomised, controlled phase 2 study was conducted in 53 pre-pubertal, hGH-naïve GHD children randomised to receive one of three MOD-4023 doses as a once-weekly s.c. injection (0.25, 0.48,...

hrp0097lb17 | Late Breaking | ESPE2023

The Majority of Children with Pediatric Growth Hormone Deficiency Treated With Lonapegsomatropin for Up To 6 Years Met or Exceeded Average Parental Height SDS: Final Results of enliGHten

Vlachopapadopoulou Elpis , Thornton Paul , Hofman Paul , Nadgir Ulhas , Saenger Paul , Malievskiy Oleg , Aghajanova Elena , Korpal-Szczyrska Maria , Mao Meng , Abdelrahman Sohair , Komirenko Allison , Shu Aimee , Maniatis Aristides

Introduction: Lonapegsomatropin (SKYTROFA, TransCon hGH), a prodrug of somatropin administered once-weekly, is approved for the treatment of pediatric growth hormone deficiency (GHD) by the Food and Drug Administration and European Commission. In the pivotal 52-week phase 3 heiGHt trial and 26-week fliGHt trial (enrolled treatment-naïve and treatment-experienced participants, respectively), lonapegsomatropin demonstrated safety and efficacy in children wi...

hrp0089rfc4.5 | GH & IGFs | ESPE2018

12-Month Effects of Once-Weekly and Twice-Monthly Administration of Hybrid Fc-Fused Human Growth Hormone, GX-H9, Treatment in Pediatric with GHD Deficiency

Malievskiy Oleg , Mykola Aryaev , Nataliya Zelinska , Bolshova Elena V , Senatorova Ganna , Oroszlan Gyorgy , Skorodok Julia , Peterkova Valentina , Nataliya Chorna , Sorokman Tamila , Yang Seung , Lee Ji Eun , Muzsnai Agota , Hwang Jin Soon , Lee Sang Yoon , Choi Yun Jung , Ji Hyi-Jeong , Woo Jungwon , Sung Young-Chul

GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults and children with GH deficiency (GHD). This study was designed to compare 12-month effects of once-weekly and twice-monthly (every other week; EOW) administration of GX-H9 treatment to that of Genotropin®, in pediatric patients with GHD. A randomized, open-label, active-controlled, parallel study was conducted at 27 endocrinology centers in 10 countries (Europe and Ko...

hrp0089p2-p100 | Diabetes & Insulin P2 | ESPE2018

The Glycemic Variability in Children with Diabetes Mellitus

Dianov Oleg , Lavrova Ekaterina , Gnusaev Sergey

The glycemic variability (GV) - is the scope of changes in blood glucose levels for a certain period of time. In patients with diabetes mellitus type 1 (DM1), GV are more pronounced, especially in children. The aim: analyze the glycemic variability in children with diabetes mellitus.Materials and methods: 126 children aged from 6 to 17 years with duration from DM 16 years were examined. Investigated: glycated hemoglobin (HbA1c), insulin ...

hrp0084p2-302 | Diabetes | ESPE2015

The Impact of Diurnal Glycaemic Variability on the Cardiovascular System in Children with Type 1 Diabetes Mellitus

Dianov Oleg , Gnusaev Sergey , Lavrova Ekaterina

Background: Diurnal glycaemic variability has a direct impact on the formation of chronic complications of type 1 diabetes mellitus (T1DM) in children.Aim: To clinically assess the function of the cardiovascular system depending on the diurnal glycaemic variability in children with T1DM.Material and methods: The study involved 65 children (30 girls and 35 boys) aged 4–17 years (mean age – 11+0.4 years old) with T1DM durat...

hrp0092p3-129 | Fat, Metabolism and Obesity | ESPE2019

Influence of Anthropometric Indices at Birth on Obesity Characteristics in School-Age Children

Latyshev Dmitry , Latyshev Oleg , Lobanov Yuri , Karkova Tatyana

Influence of anthropometric indices at birth on obesity characteristics in school-age children Latyshev D. Yu., Lobanov Yu. F.? Latyshev O. Yu. *, Karkova T.A. Altai State Medical University, Barnaul * Russian Medical Academy of Postgraduate Education. Moscow Keywords: obesity, children, body length, body mass index Objective: To study the relationship between anthropometric data at birth and the course of obesity in school-age children. Materials and metho...